A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Condition(s) studied
Investigational drug(s) / intervention(s)
Telisotuzumab Adizutecan: Intravenous (IV)
Pembrolizumab: IV
Carboplatin: IV
Cisplatin: IV
Fluorouracil: IV
Study summary
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combination with pembrolizumab as first-line treatment in participants with recurrent or metastatic head and neck squamous cell carcinoma.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of recurrent or metastatic HNSCC. Participants are placed into 3 treatment groups called treatment arms. Each group receives a different treatment. Adult participants diagnosed with recurrent or metastatic HNSCC who have not received prior systemic therapy for advanced disease and whose tumors express c-Met protein will be enrolled. Approximately 180 participants will be enrolled in the study at sites worldwide.
Participants will receive intravenous doses of telisotuzumab adizutecan with intravenous pembrolizumab, or standard of care (SOC) chemotherapy with pembrolizumab. Participants will receive treatment as part of a 67 weeks study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits every 3 weeks during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Eligibility
Primary outcome measure(s)
- Number of Participants with Adverse Events (AE)s — Up to Approximately 67 weeks
An AE is defined as any untoward medical occurrence, inappropriate patient management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. - Objective Response (OR) Rate Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 — Up to Approximately 67 weeks
OR is defined as participants achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. - Progression-Free Survival (PFS) Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 — Up to Approximately 67 weeks
PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first.
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| City Of Hope Comprehensive Cancer Center /ID# 281939 | Duarte | California | Recruiting |
| City of Hope - Atlanta /ID# 285268 | Newnan | Georgia | Recruiting |
| Kobe University Hospital /ID# 281770 | Kobe | Hyōgo | Recruiting |
| China Medical University Hospital /ID# 281502 | Taichung | Taiwan | Recruiting |
| Taipei Veterans General Hospital /ID# 281531 | Taipei | Taiwan | Recruiting |
On this site
📄 Keytruda (pembrolizumab) drug profile →More AbbVie trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07744126 on ClinicalTrials.gov ↗ ← All trials in the USA